Chronic Lymphocytic Leukaemia (CLL)
Conditions
Keywords
Acalabrutinib
Brief summary
Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany.
Detailed description
This observational study will prospectively assess acalabrutinib therapy retention of CLL patients one year and 2 years after treatment initiation with acalabrutinib in routine clinical practice. Furthermore, therapy adherence, treatment efficacy, overall survival, and QoL to analyse the possible influence of psychological aspects of the patient-based disease perception, a four-group-segmentation for acceptance and perceived control of the health state will be conducted. Finally, disease-, treatment-, and patient-specific factors possibly affecting therapy retention will be analysed: sociodemographic factors, disease and treatment characteristics, comorbidities, therapy adherence, treatment effectiveness, safety, QoL, and psychological segmentation.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Diagnosis of CLL * Ability to understand the study concept and to regularly complete patient questionnaires from physical, mental, and linguistic perspectives * Decision to start therapy with acalabrutinib according to the current SmPC. For previously untreated patients as continuous therapy with or without obinutuzumab. OR For patients with at least one prior CLL therapy as continuous monotherapy. * Provision of signed informed consent form
Exclusion criteria
* Current or planned participation in an interventional clinical trial * Contraindications to treatment with acalabrutinib according to the current SmPC * Pregnancy or breast feeding * Disease progression on prior BTKi therapy * Start of acalabrutinib therapy more than 28 days prior to enrolment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Retention rate of CLL | 1 year | The primary outcome of this study is the retention rate of CLL patients receiving acalabrutinib in clinical practice after 1 year (= ratio of the number of patients still being prescribed acalabrutinib after 1 year to the number of patients at risk). Cases of death, ongoing treatment interruption, and lost to follow-up will be counted as patients not still being prescribed with acalabrutinib. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| reasons for and duration of therapy interruptions | time from first prescription until therapy interruptions; assessed up to 40 months | Based on acalabrutinib treatment details, the reasons for and duration of therapy interruptions will be calculated and analysed. |
| TTD | time from start of acalabrutinib treatment until the date of final discontinuation or death; assessed up to 40 months. | Based on acalabrutinib treatment details, the TTD, defined as the time from first prescription until the date of last intake or death, whichever occurs first, will be calculated and the reasons for therapy discontinuation will be analysed. |
| TTNT | time from start of acalabrutinib treatment until start of a subsequent CLL treatment; assessed up to 40 months. | Based on acalabrutinib treatment details, the TTNT, defined as the time of first prescription until start date of the next CLL treatment will be calculated and the reasons for switch of treatment will be analysed. Cases of death will be censored and not considered as TTNT-relevant event. |
| Retention rate of CLL | 2 years | The secondary outcome is the retention rate of CLL patients receiving acalabrutinib in clinical practice after 2 years. |
| TTNT-D | time from start of acalabrutinib treatment until start of a subsequent CLL treatment or death; assessed up to 40 months | Based on acalabrutinib treatment details, the TTNT-D, defined as the time of first prescription until start date of the next CLL treatment or death, whichever occurs first, will be calculated. |
| General treatment adherence | assessed at baseline and 6, 12, and 24 months after start of acalabrutinib treatment | General treatment adherence will be assessed over the whole observational period by the self-reported, 8-item structured MMAS-8 questionnaire. |
| Overall survival | time from start of acalabrutinib treatment until death by any cause; assessed up to 40 months. | Overall survival will be calculated as the time from first prescription until death by any cause. |
| Patient- and disease-specific factors possibly affecting the retention rate | up to 40 months | Patient- and disease-specific factors possibly affecting the retention rate will be analysed for associations with the following variables: \- Treatment effectiveness (treatment response, PFS) |
| Healths-related Quality of Life (HRQoL)-QLQ-C30 | Patient questionnaires will becollected at time points synchronised with regular visits during study, assessed up to 40 months | The QoL, as measured by the self-reported QLQ-C30 questionnaires, will be assessed at baseline and every quarterly regular follow-up visit thereafter until end of observation. The time course of the QoL will be visualised and the mean difference from baseline until 6, 12, and 24 months after start of therapy will be calculated. Clinical significance will be defined as minimal important differences (MIDs) of at least 10 points (in either direction) for total scores or subscales of the QLQ-C30. |
| Healths-related Quality of Life (HRQoL)-EQ-5D-5L | Patient questionnaires will becollected at time points synchronised with regular visits during study, assessed up to 40 months | The QoL, as measured by the self-reported EQ-5D-5L questionnaires, will be assessed at baseline and every quarterly regular follow-up visit thereafter until end of observation. The time course of the QoL will be visualised and the mean difference from baseline until 6, 12, and 24 months after start of therapy will be calculated. |
| Patient- and disease-specific factors possibly affecting the retention rate (Psychological patient segmentation) | at Baseline | Psychological patient segmentation as determinant for the disease acceptance and disease control will be performed during the baseline visit by using a questionnaire published by Bloem et al. in 2020 |
| Treatment efficacy and PFS | time from start of acalabrutinib treatment until disease progression or death by any cause, whichever occurs first; assessed up to 40 months. | Treatment efficacy will be analysed by means of the overall treatment response (CR, PR, PRL, judged by the treating physician and recommended to be in accordance with the guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), modified for persistent lymphocytosis, the time to and duration of response, the percentage of patients without treatment response (SD, PD), as well as the time of PFS, defined as the time of first prescription until progression of the disease or death by any cause, whichever occurs first. |
Countries
Germany
Outcome results
None listed